SARS-CoV-2 Vaccines: Status Report

Immunity. 2020 Apr 14;52(4):583-589. doi: 10.1016/j.immuni.2020.03.007. Epub 2020 Apr 6.

Abstract

SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity*
  • China
  • Clinical Trials as Topic
  • Coronavirus / pathogenicity
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / prevention & control*
  • Disease Models, Animal
  • Drug Development*
  • Humans
  • Pandemics / prevention & control*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / prevention & control*
  • Time Factors
  • Viral Vaccines* / therapeutic use

Substances

  • COVID-19 vaccine
  • Viral Vaccines

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2